Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II

Beckman, Joshua A.; Paneni, Francesco; Cosentino, Francesco; Creager, Mark A.

doi:10.1093/eurheartj/eht142

Cited by 434Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and ManagementDiabetes Management and Research

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II

Open access

Beckman, Joshua A., Paneni, Francesco, Cosentino, Francesco, Creager, Mark A.·2013·European Heart Journal

DOI 10.1093/eurheartj/eht142

Open this paper in CoChat — free account Open PDF

Abstract

In part II of this review, we describe the epidemiology and clinical consequences of vascular disease in patients with diabetes, and discuss the efficacy of risk factor modification and antiplatelet treatment. Specifically, evidence-based cardiovascular therapies are discussed through novel clinical insights on management of hyperglycaemia, hypertension, dyslipidaemia as well as platelet dysfunction. Recent trends in the incidence and outcomes of vascular disease in diabetes suggest that timely and effective implementation of therapies is making a favourable impact.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/eurheartj/eht142

Cites

154 of 154 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Free radicals impair β-cell function and insulin sensitivity, contributing to hyperglycemia and insulin resistance, which could further promote the development of CVD.
“Free radicals also impair β-cell function and insulin sensitivity, contributing to hyperglycemia and insulin resistance, which could further promote the development of CVD.”
From Micronutrient Supplementation to Reduce Cardiovascular Risk (2022) · cites this paper as [18]
The Hyperglycaemia section (p. 5) links elevated glucose levels with increased cardiovascular-event risk, and the Coronary heart disease section (p. 3) reports that insulin resistance is common among patients with coronary disease. But the paper does not say that free radicals impair β-cell function or insulin sensitivity, so it does not support the proposed mechanism. (LLM, conf=0.84)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · see citing works
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271 · see citing works
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · see citing works
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · see citing works
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247 · see citing works
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888 · see citing works
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · see citing works
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · see citing works
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117 · see citing works
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000 · see citing works
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992 · see citing works
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943 · see citing works
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
(1998) · BMJ · doi:10.1136/bmj.317.7160.703 · Cited by 6,683 · see citing works
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503 · see citing works
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470 · see citing works
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220 · see citing works
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866 · see citing works
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728 · see citing works
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664 · see citing works
Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010.
Flegal, K., Carroll, M., Kit, B., & Ogden, C. (2012) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2012.39 · Cited by 5,523 · see citing works
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125 · see citing works
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941 · see citing works
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · see citing works
Optimal Medical Therapy with or without PCI for Stable Coronary Disease
Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070829 · Cited by 4,699 · see citing works
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · see citing works
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · see citing works
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
(2009) · The Lancet · doi:10.1016/s0140-6736(09)60503-1 · Cited by 3,675 · see citing works
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598 · see citing works
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502 · see citing works
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,489 · cited 1× · see citing works
“In the Steno-2 trial, 160 patients with type 2 diabetes were randomized to intensive therapyorconventional therapy and followed for up to 13 years.(149) Intensive therapy was defined as haemoglobin A1c ,6.”
Method
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study
O'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., Rangarajan, S., Islam, S., Pais, P., McQueen, M. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60834-3 · Cited by 3,448 · see citing works
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · see citing works
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · see citing works
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207 · see citing works
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111 · see citing works
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911 · see citing works
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · see citing works
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Sleight, R. B., Sleight, P., Parish, S., Appleby, P. N., Collins, R., & Baigent, C. (1988) · PubMed · Cited by 2,868 · see citing works
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · see citing works
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,819 · see citing works
Self-citation
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614 · see citing works
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
Julius, S., Kjeldsen, S. E., Weber, M. A., Brunner, H. R., Ekman, S., Hansson, L., Hua, T. A., Laragh, J. H., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16451-9 · Cited by 2,546 · see citing works
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471 · see citing works
The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010
Amos, A., Mccarty, D. J., & Zimmet, P. (1997) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199712)14:5+ · Cited by 2,247 · see citing works
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14286-9 · Cited by 2,142 · see citing works
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065 · see citing works
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054 · see citing works
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036 · see citing works
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939 · see citing works
Strategies for Multivessel Revascularization in Patients with Diabetes
Farkouh, M. E., Domanski, M., Sleeper, L. A., Siami, F. S., Dangas, G., Mack, M., Yang, M., Cohen, D. J., Rosenberg, Y., Solomon, S. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211585 · Cited by 1,922 · see citing works
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years
Coutinho, M., Gerstein, H. C., Wang, Y., & Yusuf, S. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.233 · Cited by 1,685 · see citing works
Diabetes and Vascular Disease
Creager, M. A., Lüscher, T. F., of, P. W. T. A., Cosentino, F., & Beckman, J. A. (2003) · Circulation · doi:10.1161/01.cir.0000091257.27563.32 · Cited by 1,654 · see citing works
Self-citation
Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624 · see citing works
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623 · see citing works
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560 · see citing works
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Ray, K. K., Seshasai, S. R. K., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., & Sattar, N. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60697-8 · Cited by 1,383 · see citing works
Guidelines on the management of stable angina pectoris: executive summary
Authors/Task Force Members, Fox, K. M., Garcia, M. A. A., Ardissino, D., Buszman, P. E., Camici, P. G., Crea, F., Daly, C., Backer, G. D., Hjemdahl, P., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl001 · Cited by 1,324 · see citing works
Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study
Norhammar, A., Tenerz, Å., Nilsson, G., Hamsten, A., Efendíc, S., Rydén, L., & Malmberg, K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09089-x · Cited by 1,112 · see citing works
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977 · see citing works
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874 · see citing works
Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes: The DIAD Study: A Randomized Controlled Trial
Young, L. H., Wackers, F. J. T., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009) · JAMA · doi:10.1001/jama.2009.476 · Cited by 809 · see citing works
High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study.
Diehm, C., Schuster, A., Allenberg, J., Darius, H., Haberl, R., Lange, S., Pittrow, D., von Stritzky, B., Tepohl, G., & Trampisch, H. (2004) · Atherosclerosis · doi:10.1016/s0021-9150(03)00204-1 · Cited by 807 · see citing works
Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
Yusuf, S., Diener, H.-C., Sacco, R. L., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804593 · Cited by 785 · see citing works
Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes<subtitle>A Randomized Controlled Trial</subtitle>
Ogawa, H. (2008) · JAMA · doi:10.1001/jama.2008.623 · Cited by 776 · see citing works
Long-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762 · see citing works
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–Thrombolysis in Myocardial Infarction 38
Wiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W. A., Goodman, S. G., Corbalan, R., Purdy, D. A., Murphy, S. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.791061 · Cited by 754 · see citing works
Effect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660 · see citing works
Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents
Kuchulakanti, P. K., Chu, W. W., Torguson, R., Ohlmann, P., Rha, S., Clavijo, L., Kim, S., Bui, A., Gevorkian, N., Xue, Z., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.600155 · Cited by 638 · see citing works
The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart
BARTNIK, M. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.07.027 · Cited by 617 · see citing works
Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005
Preis, S. R., Hwang, S., Coady, S., Pencina, M. J., D’Agostino, R. B., Savage, P. J., Levy, D. A., & Fox, C. S. (2009) · Circulation · doi:10.1161/circulationaha.108.829176 · Cited by 615 · see citing works
Rosiglitazone Revisited
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 590 · see citing works
Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk
Schramm, T. K., Gislason, G., Køber, L., Rasmussen, S., Rasmussen, J. N., Abildstrom, S. Z., Hansen, M. L., Folke, F., Buch, P., Madsen, M. M., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.720847 · Cited by 536 · see citing works
Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-6-200903170-00008 · Cited by 533 · see citing works
Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary Syndromes The MERLIN-TIMI 36 Randomized Trial
Morrow, D. A. (2007) · JAMA · doi:10.1001/jama.297.16.1775 · Cited by 507 · see citing works
Primary and Secondary Prevention of Cardiovascular Disease
Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., & Spencer, F. A. (2012) · Chest · doi:10.1378/chest.11-2306 · Cited by 476 · see citing works
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
Skyler, J. S., Bergenstal, R. M., Bonow, R. O., Buse, J. B., DEEDWANIA, P. C., Gale, E. A., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P. D., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.008 · Cited by 469 · see citing works
Probing Cold Dense Nuclear Matter
Subedi, R., Shneor, R., Monaghan, P., et al. (2008) · Science · doi:10.1126/science.1156675 · Cited by 458 · see citing works
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
James, S., Angiolillo, D. J., Cornel, J. H., Erlinge, D., Husted, S., Kontny, F., Maya, J., Nicolau, J. C., Spinar, J., Storey, R. F., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq325 · Cited by 446 · see citing works
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Schramm, T. K., Gislason, G. H., Vaag, A., Rasmussen, J. N., Folke, F., Hansen, M. L., Fosbøl, E. L., Køber, L., Norgaard, M. L., Madsen, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr077 · Cited by 418 · see citing works
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus
Bhatt, D. L., Marso, S. P., Hirsch, A. T., Ringleb, P. A., Hacke, W., & Topol, E. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02567-5 · Cited by 409 · see citing works
Diabetes and Vascular Disease
Lüscher, T. F., Creager, M. A., Beckman, J. A., & Cosentino, F. (2003) · Circulation · doi:10.1161/01.cir.0000089189.70578.e2 · Cited by 392 · see citing works
Self-citation
Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes
Sever, P. S., Poulter, N. R., Dahlöf, B., Wedel, H., Collins, R., Beevers, G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1151 · Cited by 390 · see citing works
Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s
Fox, C. S., Pencina, M. J., Meigs, J. B., Vasan, R. S., Levitzky, Y. S., & D’Agostino, R. B. (2006) · Circulation · doi:10.1161/circulationaha.106.613828 · Cited by 378 · see citing works
Is diabetes a coronary risk equivalent? Systematic review and meta‐analysis
Bulugahapitiya, U., Siyambalapitiya, S., Sithole, J., & IDRIS, I. R. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02640.x · Cited by 377 · see citing works
Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis Metformin Use With Diabetes and Atherothrombosis
Roussel, R. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.409 · Cited by 356 · see citing works
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Rajamani, K., Colman, P. G., Li, L. P., Best, J. D., Voysey, M., D'Emden, M. C., Laakso, M., Baker, J. R., & Keech, A. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60698-x · Cited by 328 · see citing works
Peripheral arterial disease in diabetes—a review
Jude, E., Eleftheriadou, I., & Tentolouris, N. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02866.x · Cited by 321 · see citing works
Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose
Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R. J., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2713 · Cited by 313 · see citing works
Trends in Death Rates Among U.S. Adults With and Without Diabetes Between 1997 and 2006
Gregg, E. W., Cheng, Y. J., Saydah, S., Cowie, C. C., GARFIELD, S. A., Geiss, L. S., & Barker, L. E. (2012) · Diabetes Care · doi:10.2337/dc11-1162 · Cited by 301 · see citing works
Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study
van Wijk, I., Kappelle, L. J., van Gijn, J., Koudstaal, P. J., Franke, C. L., Vermeulen, M., Gorter, J. W., & Algra, A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66734-7 · Cited by 296 · see citing works
A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus
Bangalore, S., Parkar, S., Grossman, E., & Messerli, F. H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.057 · Cited by 290 · see citing works
Temporal changes in prevalence of diabetes and impaired glucose tolerance associated with lifestyle transition occurring in the rural population in India
Snehalatha, C., Baskar, A. D. S., Mary, S., Sathish�Kumar, C. K., Selvam, S., Catherine, S., Viswanathan, V., & Ramachandran, A. (2004) · Diabetologia · doi:10.1007/s00125-004-1387-6 · Cited by 257 · see citing works
Combination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245 · see citing works
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes
Pignone, M. P., Alberts, M. J., Colwell, J. A., Cushman, M., Inzucchi, S. E., Mukherjee, D., Rosenson, R. S., Williams, C. D., Wilson, P. W. F., & Kirkman, M. S. (2010) · Diabetes Care · doi:10.2337/dc10-0555 · Cited by 241 · see citing works
Comparisons of Baseline Demographics, Clinical Presentation, and Long-Term Outcome Among Patients With Early, Late, and Very Late Stent Thrombosis of Sirolimus-Eluting Stents
Kimura, T., Morimoto, T., Kozuma, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.903955 · Cited by 239 · see citing works
Effect of the ACE Inhibitor Lisinopril on Mortality in Diabetic Patients With Acute Myocardial Infarction
Zuanetti, G., Latini, R., Maggioni, A. P., et al. (1997) · Circulation · doi:10.1161/01.cir.96.12.4239 · Cited by 237 · see citing works
Functional recovery after ischemic stroke—A matter of age
Knoflach, M., Matošević, B., Rücker, M., Furtner, M. T., Mair, A., Wille, G., Zangerle, A., Werner, P., Ferrari, J., Schmidauer, C., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31824367ab · Cited by 226 · see citing works
Prospective Study of Type 1 and Type 2 Diabetes and Risk of Stroke Subtypes
Janghorbani, M., Hu, F. B., Willett, W. C., Li, T. Y., Manson, J. E., Logroscino, G., & Rexrode, K. M. (2007) · Diabetes Care · doi:10.2337/dc06-2363 · Cited by 212 · see citing works
Risk Factors for Stent Thrombosis After Implantation of Sirolimus-Eluting Stents in Diabetic and Nondiabetic Patients
Machecourt, J., Danchin, N., Lablanche, J. M., Fauvel, J. M., Bonnet, J., Marlière, S., Foote, A., Quesada, J. L., Eltchaninoff, H., & Vanzetto, G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.051 · Cited by 207 · see citing works
Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis
Cayla, G., Hulot, J., O’Connor, S. A., Pathak, A., Scott, S. A., Gruel, Y., Silvain, J., Vignalou, J.-B., Huerre, Y., Briolle, A. D. L., et al. (2011) · JAMA · doi:10.1001/jama.2011.1529 · Cited by 202 · see citing works
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
Timmis, A. D., Chaitman, B. R., & Crager, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi495 · Cited by 193 · see citing works
Declining Rates of Hospitalization for Nontraumatic Lower-Extremity Amputation in the Diabetic Population Aged 40 Years or Older: U.S., 1988–2008
Li, Y., Burrows, N. R., Gregg, E. W., Albright, A. L., & Geiss, L. S. (2012) · Diabetes Care · doi:10.2337/dc11-1360 · Cited by 189 · see citing works
Nationally Representative Surveys Show Recent Increases in the Prevalence of Overweight and Obesity among Women of Reproductive Age in Bangladesh, Nepal, and India
Balarajan, Y., & Villamor, E. (2009) · Journal of Nutrition · doi:10.3945/jn.109.112029 · Cited by 188 · see citing works
Meta-Analysis of Multiple Primary Prevention Trials of Cardiovascular Events Using Aspirin
Bartolucci, A. A., Tendera, M., & Howard, G. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.02.325 · Cited by 185 · see citing works
Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial
Morrow, D. A., Scirica, B. M., Chaitman, B. R., McGuire, D. K., Murphy, S. A., Karwatowska-Prokopczuk, E., McCabe, C. H., & Braunwald, E. (2009) · Circulation · doi:10.1161/circulationaha.107.763912 · Cited by 170 · see citing works
Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease
Raju, N. C., Sobieraj‐Teague, M., Hirsh, J., O'Donnell, M. J., & Eikelboom, J. W. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.01.018 · Cited by 168 · see citing works
Natural history of claudication: Long-term serial follow-up study of 1244 claudicants
Aquino, R. V., Johnnides, C., Makaroun, M. S., Whittle, J., Muluk, V. S., Kelley, M. E., & Muluk, S. C. (2001) · Journal of Vascular Surgery · doi:10.1067/mva.2001.119749 · Cited by 162 · see citing works
Diabetes and Poor Outcomes Within 6 Months After Acute Ischemic Stroke
Jia, Q., Zhao, X., Wang, C., Wang, Y., Yan, Y., Li, H., Zhong, L., Liu, L., Zheng, H., Zhou, Y., et al. (2011) · Stroke · doi:10.1161/strokeaha.111.621649 · Cited by 152 · see citing works
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy
Daly, C., Fox, K. M., Remme, W. J., Bertrand, M. E., Ferrari, R., & Simoons, M. L. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi225 · Cited by 133 · see citing works
Effect of Diabetes and Associated Conditions on Long-Term Survival After Coronary Artery Bypass Graft Surgery
Leavitt, B. J., Sheppard, L., Maloney, C. T., et al. (2004) · Circulation · doi:10.1161/01.cir.0000138197.07051.e7 · Cited by 131 · see citing works
Rationale and Design for the Blood Pressure Intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
Cushman, W. C., Grimm, R. H., Cutler, J. A., Evans, G. W., Capes, S., Corson, M. A., Sadler, L. S., Alderman, M. H., Peterson, K., Bertoni, A., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.005 · Cited by 123 · see citing works
Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial
Estacio, R. O., & Schrier, R. W. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00750-4 · Cited by 123 · see citing works
Risk of Stroke and Cardiovascular Events After Ischemic Stroke or Transient Ischemic Attack in Patients With Type 2 Diabetes or Metabolic Syndrome
Callahan, A. S., III (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.146 · Cited by 112 · see citing works
Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial
Ahmed, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl220 · Cited by 110 · see citing works
Prevalence of Neuropathy and Peripheral Arterial Disease and the Impact of Treatment in People With Screen-Detected Type 2 Diabetes
Charles, M., Ejskjær, N., Witte, D. R., Borch‐Johnsen, K., Lauritzen, T., & Sandbæk, A. (2011) · Diabetes Care · doi:10.2337/dc11-0903 · Cited by 109 · see citing works
Uniformity of captopril benefit in the SAVE study: subgroup analysis
Moyé, L. A., Pfeffer, M. A., Wun, C. C., Davis, B. R., Geltman, E. M., Hayes, D. L., Farnham, D. J., Randall, O. S., Dinh, H., Arnold, J. M. O., et al. (1994) · European Heart Journal · doi:10.1093/eurheartj/15.suppl_b.2 · Cited by 107 · see citing works
Trends in the Risk for Coronary Heart Disease Among Adults With Diagnosed Diabetes in the U.S.
Ford, E. S. (2011) · Diabetes Care · doi:10.2337/dc10-2251 · Cited by 104 · see citing works
Trends in the Prevalence, Awareness, Treatment, and Control of Cardiovascular Disease Risk Factors among Noninstitutionalized Patients with a History of Myocardial Infarction and Stroke
Muntner, P., DeSalvo, K. B., Wildman, R. P., Raggi, P., He, J., & Whelton, P. K. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj124 · Cited by 101 · see citing works
Blood Pressure J-Curve: Current Concepts
Banach, M., & Aronow, W. S. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0314-3 · Cited by 100 · see citing works
Trends in Lower-Extremity Amputations in People With and Without Diabetes in Spain, 2001–2008
López‐de‐Andrés, A., Martinez-Huedo, M. A., Carrasco‐Garrido, P., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0077 · Cited by 99 · see citing works
Prevalence of Type 2 diabetes in urban and rural Chinese populations in Qingdao, China
Dong, Y., Gao, W., Nan, H., Yu, H., Li, F., Duan, W., Wang, Y., Sun, B., Qian, R., Tuomilehto, J. O., et al. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01658.x · Cited by 99 · see citing works
Mortality Rates in Trials of Subjects With Type 2 Diabetes
Barkoudah, E., Skali, H., Uno, H., Solomon, S. D., & Pfeffer, M. A. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.111.000059 · Cited by 97 · see citing works
Age standardization in mapping adult overweight and obesity trends in the WHO European Region
Doak, C. M., Wijnhoven, T. M. A., Schokker, D. F., Visscher, T. L. S., & Seidell, J. C. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2011.00943.x · Cited by 96 · see citing works
Long-Term Impact of Diabetes and Its Comorbidities in Patients Undergoing Isolated Primary Coronary Artery Bypass Graft Surgery
Mohammadi, S., Dagenais, F., Mathieu, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.681320 · Cited by 88 · see citing works
Stroke Incidence and Mortality Rates 1987 to 2006 Related to Secular Trends of Cardiovascular Risk Factors in Gothenburg, Sweden
Harmsen, P., Wilhelmsen, L., & Jacobsson, A. (2009) · Stroke · doi:10.1161/strokeaha.109.550814 · Cited by 83 · see citing works
Trends in Risk Factors, Stroke Subtypes and Outcome
Arboix, A., Cendrós-Cámara, V., Besa, M., et al. (2008) · Cerebrovascular Diseases · doi:10.1159/000155989 · Cited by 82 · see citing works
Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: Findings from the National Health and Nutrition Examination Survey 1999-2008*
Ford, E. S. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00148.x · Cited by 79 · see citing works
Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population‐based study
Monesi, L., Baviera, M., Marzona, I., et al. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03446.x · Cited by 77 · see citing works
Usefulness of Atherogenic Dyslipidemia for Predicting Cardiovascular Risk in Patients With Angiographically Defined Coronary Artery Disease
Arca, M., Montali, A., Valiante, S., Campagna, F., Pigna, G., Paoletti, V., Antonini, R., Barillà, F., Tanzilli, G., Vestri, A., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.049 · Cited by 75 · see citing works
Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease
Shepherd, J., Kastelein, J. J. P., Bittner, V., Carmena, R., DEEDWANIA, P. C., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A. L., & WENGER, N. K. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.8.870 · Cited by 71 · see citing works
Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction
Jensen, L. O., Mæng, M., Thayssen, P., Tilsted, H. H., Terkelsen, C. J., Kaltoft, A., Lassen, J. F., Hansen, K. N., Ravkilde, J., Christiansen, E. H., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.10.018 · Cited by 65 · see citing works
Differential Secretion of Atrial and Brain Natriuretic Peptide in Critically Ill Patients
Berendes, E., Aken, H. V., Raufhake, C., et al. (2001) · Anesthesia & Analgesia · doi:10.1097/00000539-200109000-00029 · Cited by 60 · see citing works
A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design
Preiss, D., Sattar, N. A., & McMurray, J. J. V. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.10.019 · Cited by 58 · see citing works
Prevalence and clinical profile and management of peripheral arterial disease in elderly patients with diabetes.
Escobar, C., Blanes, I., Ruiz, A., Vinuesa, D., Montero, M., Rodríguez, M., Barberá, G., & Manzano, L. (2011) · European journal of internal medicine · doi:10.1016/j.ejim.2011.02.001 · Cited by 58 · see citing works
Association of diabetes, homocysteine, and HDL with cognition and disability after stroke
Newman, G. C., Bang, H., Hussain, S. I., & Toole, J. F. (2007) · Neurology · doi:10.1212/01.wnl.0000280457.29680.9c · Cited by 55 · see citing works
Trends in Initial Lower Extremity Amputation Rates Among Veterans Health Administration Health Care System Users From 2000 to 2004
Tseng, C., Rajan, M., Miller, D. R., Lafrance, J., & POGACH, L. M. (2011) · Diabetes Care · doi:10.2337/dc10-1775 · Cited by 53 · see citing works
The Influence of Type 2 Diabetes Mellitus in Patients Undergoing Coronary Artery Bypass Graft Surgery
Woods, S. E., Smith, J. M., Sohail, S., et al. (2004) · CHEST Journal · doi:10.1378/chest.126.6.1789 · Cited by 52 · see citing works
Angiotensin-converting enzyme inhibition after myocardial infarction: the trandolapril cardiac evaluation study
Torp-Pedersen, C., Køber, L., & Carlsen, J. E. (1996) · American Heart Journal · doi:10.1016/s0002-8703(96)90559-1 · Cited by 40 · see citing works
Increasing trend in the prevalence of Type 2 diabetes and pre‐diabetes in the Chinese rural and urban population in Qingdao, China
Gao, W., Dong, Y. H., Pang, Z., Nan, H. R., Zhang, L., Wang, S., Ren, J., Ning, F., Qiao, Q., & for the Qingdao 2006 Diabetes Survey Group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02832.x · Cited by 37 · see citing works
Newly diagnosed glucose intolerance and prognosis after acute myocardial infarction: comparison of post-challenge versus fasting glucose concentrations
Tamita, K., Katayama, M., Takagi, T., Yamamuro, A., Kaji, S., Yoshikawa, J., & Furukawa, Y. (2012) · Heart · doi:10.1136/heartjnl-2012-301629 · Cited by 36 · see citing works
Spironolactone in Patients with Heart Failure
Larkin, R. J., Atlas, S., & Donohue, T. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001133420213 · Cited by 35 · see citing works
Prevalence and determinants of undiagnosed diabetes in an urban sub-Saharan African population
Echouffo-Tcheugui, J. B., Dzudié, A., Ewane, M. E., Choukem, S. P., Doualla, M. S., Luma, H. N., & Kengne, A. P. (2012) · Primary care diabetes · doi:10.1016/j.pcd.2012.05.002 · Cited by 34 · see citing works
Incidence of critical limb ischemia and amputation outcome in contralateral limb in diabetic patients hospitalized for unilateral critical limb ischemia during 1999–2003 and followed-up until 2005
Faglia, E., Clerici, G., Mantero, M., et al. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.01.010 · Cited by 29 · see citing works
High Prevalence of Peripheral Arterial Disease but Low Antiplatelet Treatment Rates in Elderly Primary Care Patients With Diabetes
Lange, S., Diehm, C., Darius, H., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3357 · Cited by 27 · see citing works
Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998–2004: a longitudinal observational study
Greving, J. P., Denig, P., de Zeeuw, D., Bilo, H. J. G., & Haaijer‐Ruskamp, F. M. (2007) · Cardiovascular Diabetology · doi:10.1186/1475-2840-6-25 · Cited by 24 · see citing works
Prognosis of Ischaemic Stroke is Improving Similarly in Patients with Type 2 Diabetes as in Nondiabetic Patients in Finland
Winell, K., Pääkkönen, R., Pietilä, A., Reunanen, A., Niemi, M., & Salomaa, V. V. (2011) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00567.x · Cited by 21 · see citing works
Temporal trends in diabetes prevalence and key diabetes risk factors in Scotland, 2003–2008
Hamer, M., Kengne, A. P., Batty, G. D., Cooke, D. D., & Stamatakis, E. A. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03254.x · Cited by 19 · see citing works
Diabetes-related major lower limb amputation in Far North Queensland, 1998–2008
O'Rourke, S. R., Steffen, C. M., Raulli, A., et al. (2012) · Australian Health Review · doi:10.1071/ah10969 · Cited by 17 · see citing works
Time trends in absolute and modifiable coronary heart disease risk in patients with Type 2 diabetes in the Swedish National Diabetes Register (NDR) 2003–2008
Fhärm, E., Cederholm, J., Eliasson, B., Guðbjörnsdóttir, S., & Rolandsson, O. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03425.x · Cited by 17 · see citing works
Incidence of Self-Reported Diabetes in New York City, 2002, 2004, and 2008
Tabaei, B. P., Chamany, S., Driver, C., Kerker, B. D., & Silver, L. D. (2012) · Preventing Chronic Disease · doi:10.5888/pcd9.110320 · Cited by 16 · see citing works
Trends in population attributable fraction of acute coronary syndrome and ischaemic stroke due to diabetes in Finland
Winell, K., Pietilä, A., Niemi, M., Reunanen, A., & Salomaa, V. V. (2011) · Diabetologia · doi:10.1007/s00125-011-2262-x · Cited by 8 · see citing works
Properties of olive oil
Wahrburg, U., & Assmann, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04774-7 · Cited by 7 · see citing works
Spironolactone in patients with heart failure.
Vanpee, D., & Swine, C. (2000) · PubMed · Cited by 5 · see citing works
FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents
(2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2823 · Cited by 5 · see citing works

Flagged first, then by citations

Research works printed but not linked: 13

[28]28. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomesbyoptimizingplateletinhibitionwithprasugrel-ThrombolysisinMyocardial Infarction 38. Circulation 2008; 118 :1626-1636.
[29]29. Jensen LO, Maeng M, Thayssen P, Tilsted HH, Terkelsen CJ, Kaltoft A, Lassen JF, HansenKN,RavkildeJ, Christiansen EH, Madsen M, Sorensen HT, Thuesen L. Influenceofdiabetesmellitusonclinical outcomesfollowingprimarypercutaneouscoronaryintervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2012; 109 :629-635.
[37]37. Greving JP, Denig P, de Zeeuw D, Bilo HJ, Haaijer-Ruskamp FM. Trends in hyperlipidemia and hypertension managementintype 2diabetes patientsfrom1998-2004: a longitudinal observational study. Cardiovasc Diabetol 2007; 6 :25.
[38]38. FharmE,CederholmJ,EliassonB,GudbjornsdottirS, RolandssonO.Time trendsin absoluteandmodifiablecoronaryheartdiseaseriskinpatientswithType2diabetes in the Swedish National Diabetes Register (NDR) 2003-2008. Diabet Med 2012; 29 :198-206.
[62]62. CharlesM,EjskjaerN,WitteDR,Borch-JohnsenK,Lauritzen T,Sandbaek A.Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in peoplewithscreen-detectedtype2diabetes:theADDITION-Denmarkstudy. Diabetes Care 2011; 34 :2244-2249.
[65]65. Lopez-de-Andres A, Martinez-Huedo MA, Carrasco-Garrido P, Hernandez-Barrera V, Gil-de-Miguel A, Jimenez-Garcia R. Trends in lowerextremity amputations in people with and without diabetes in Spain, 20012008. Diabetes Care 2011; 34 :1570-1576.
[77]77. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, Ravaud P, MarreM,PorathA,BhattDL,StegPG.Metforminuseandmortalityamongpatients with diabetes and atherothrombosis. Arch Intern Med 2010; 170 :1892-1899.
[78]78. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbol EL, Kober L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared withmetforminintype2diabetes,withorwithoutapreviousmyocardialinfarction: a nationwide study. Eur Heart J 2011; 32 :1900-1908.
[82]82. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance andHbA1cinpatientswithchronicanginaanddiabetes. EurHeartJ 2006; 27 :42-48.
[86]86. HolmanRR,PaulSK,BethelMA,NeilHA,MatthewsDR.Long-termfollow-upafter tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359 : 1565-1576.
[20]20. myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349 :1893-1906.
[20]20. events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300 :2134-2141.
[143]143. BhattDL,MarsoSP,HirschAT,RinglebPA,HackeW,TopolEJ.Amplifiedbenefitof clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90 : 625-628.

Sorted by citations

Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697 · see citing works
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381 · see citing works
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): <i>Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society</i>
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Moss, A. J., Myerburg, R. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.178233 · Cited by 1,080 · see citing works
Sex differences in cardiovascular risk factors and disease prevention
Appelman, Y., van Rijn, B. B., ten Haaf, M. E., Boersma, E., & Peters, S. A. E. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.027 · Cited by 588 · see citing works
Micronutrient Supplementation to Reduce Cardiovascular Risk
An, P., Wan, S., Luo, Y., Luo, J., Zhang, X., Zhou, S., Xu, T., He, J., Mechanick, J. I., Wu, W.-C., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.09.048 · Cited by 189 · see citing works
Reducing Nontraumatic Lower-Extremity Amputations by 20% by 2030: Time to Get to Our Feet: A Policy Statement From the American Heart Association
Creager, M. A., Matsushita, K., Arya, S., Beckman, J. A., Duval, S., Goodney, P. P., Gutierrez, J. A. T., Kaufman, J. A., Joynt Maddox, K. E., Pollak, A. W., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000967 · Cited by 164 · see citing works
Self-citation
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.015 · Cited by 83 · see citing works
Self-citation
Epigenetic Signatures and Vascular Risk in Type 2 Diabetes: A Clinical Perspective
Paneni, F., Costantino, S., Volpe, M., Lüscher, T. F., & Cosentino, F. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.003 · Cited by 70 · see citing works
Self-citation
Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic <i>ApoE−/−</i> mice
Di Marco, E., Gray, S. P., Chew, P., Kennedy, K., Cooper, M. E., Schmidt, H. H. H. W., & Jandeleit-Dahm, K. A. M. (2016) · Clinical Science · doi:10.1042/cs20160249 · Cited by 37 · see citing works

Authors: Beckman, J. A., Paneni, F., Cosentino, F., & Creager, M. A.
Affiliations: Brigham and Women's Hospital (US)
University of Zurich (CH)
Corresponding author: Beckman, Joshua A.
ORCID: Beckman, Joshua A.
Paneni, Francesco
Cosentino, Francesco
Creager, Mark A.
Venue: European Heart Journal
Publisher: Oxford University Press (OUP)
Published: 2013-04-26
Volume: 34
Issue: 31
Pages: 2444-2452
ISSN: 0195-668X (ISSN-L)
1522-9645
DOI: 10.1093/eurheartj/eht142
OpenAlex: W4211172623
Cited by: 434
References: 154
Citations by year: 2026: 19 · 2025: 29 · 2024: 35 · 2023: 32 · 2022: 43 · 2021: 40 · 2020: 37 · 2019: 32 · 2018: 37 · 2017: 33 · 2016: 21 · 2015: 28 · 2014: 21 · 2013: 10 · 2012: 2
FWCI: 3.85
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: European Heart Journal (publishedVersion)
PubMed (publishedVersion)
Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
reroDoc Digital Library (submittedVersion)
IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
Zurich Open Repository and Archive (University of Zurich)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: diabetes mellitus, vascular disease, cardiovascular risk factors, risk factor control, antiplatelet therapy, hyperglycemia management, hypertension, dyslipidemia, platelet dysfunction, cardiovascular disease treatment
MeSH terms: Antihypertensive Agents, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Platelet Aggregation Inhibitors, Global Health, Myocardial Reperfusion, Prevalence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Risk Reduction Behavior, Dyslipidemias, Atherosclerosis, Peripheral Arterial Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks